FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to a number of substituted dihydrobenzocycloalkyloxymethyl oxazolpyrimidinone of formula
wherein n represents 1, 2 or 3; R1 represents hydrogen, methyl, fluoromethyl, ethyl, 2-fluoroethyl and propyl; R2 is specified in a group consisting of hydrogen, methyl, fluoromethyl, ethyl, 2-fluoroethyl, propyl, 1,1-difluoropropyl, methoxymethyl and 2-fluoroethoxymethyl; R3 and R4 represent (C1-C4)alkyl; and R5 and R6 are identical or different and are independently specified in a group consisting of hydrogen, halogen, (C1-C4)alkyl and (C1-C4)alkoxy. The invention also refers to specific compounds specified in cl.8 of the patent claim, to compounds of formula
a pharmaceutical composition and the use of the declared compounds.
EFFECT: dihydrobenzocycloalkyl-oxymethyloxazolpyrimidinone as metabotropic glutamate receptor mGluR2 modulators.
14 cl, 1 tbl, 15 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PRODUCTION AND USE OF SUBSTITUTED DIHYDRO- AND TETRAHYDROOXAZOLO-PYRIMIDINONES | 2008 |
|
RU2470937C2 |
| NITROIMIDAZOLE DERIVATIVE AGAINST PULMONARY TUBERCULOSIS | 2016 |
|
RU2675622C1 |
| PYRIDAZINE DERIVATIVES AS RORc MODULATORS | 2017 |
|
RU2757571C2 |
| MEDICINAL COMPOUNDS | 2014 |
|
RU2691105C1 |
| INDOLE AND BENZOXAZINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | 2009 |
|
RU2512283C2 |
| SUBSTITUTED PYRIMIDINETHIOALKYL OR ALKYLESTER COMPOUNDS AND METHOD OF INHIBITION OF VIRAL REVERSE TRANSCRIPTASE ACTIVITY | 1996 |
|
RU2167155C2 |
| AZADECALINS CONDENSED WITH HETEROARYLKETONES - GLUCOCORTICOID RECEPTOR MODULATORS | 2013 |
|
RU2639867C2 |
| COMPOUND BASED ON DIHYDRONAPTHYRIDINONE, METHOD OF ITS OBTAINING, AND ITS USE IN MEDICINE | 2021 |
|
RU2809869C1 |
| ETHYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR | 2016 |
|
RU2721776C2 |
| NOVEL CONDENSED PYRIDINE DERIVATIVES USED AS C-MET TYROSINE KINASE INHIBITORS | 2013 |
|
RU2619130C2 |
